Bioreactor Market Size By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells, Others), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy, Others), By Technology (Wave-Induced Motion SUB, Stirred SUB, Single Use Bubble Column, Other SUB), By End-Use ( R&D organizations, Biopharma Manufacturers, CMOs) Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, Spain, Italy, France, Netherland, Denmark, China, Japan, India, South Korea, Australia, Singapore, Brazil, Mexico, UAE, South Africa), Application Development, Price Trend, Competitive Landscape & Forecast, 2017 - 2024

Choose Licence

 

Bioreactor Market size is set to exceed USD 1.9 billion by 2024; according to a new research report. Rising chronic disease prevalence and growing research in the field of biopharmaceuticals will drive the global bioreactor market size. Increased focus of biopharmaceutical companies to develop effective treatment options for orphan diseases should fuel industry growth. Personalized medicines are changing the way many diseases are identified, classified, and treated. The growing personalized medicine market that involves a focused population base will further drive the bioreactor market size. A new manufacturing technology has evolved to provide more personalized drug products such as 3D bioprinting. Technological advances in manufacturing technology should improve flexibility, quality and scalability of operations with low capital and energy requirements. Innovative methods and analytical tools are projected to enhance process robustness, accelerate scale-up to industrial production and drive efficient use of resources. Biopharmaceuticals are individualized products with highly specific manufacturing requirements. Advanced biopharmaceutical manufacturing technologies have enabled the development of effective drug delivery systems and drug device combination products. Increased collaboration in biopharmaceutical industry through partnerships with medical device manufacturers, diagnostic developers, academic institutions should propel business growth. Biopharmaceutical contract manufacturing outsourcing should drive the industry growth due to rising demand for biopharmaceuticals along with innovative drug products entering the clinical trials. Large number of outsourcing services such as analytical, formulation, cell line development and small or large scale production related services should stimulate the business growth over the forecast years. Mammalian cells market revenue is estimated to exceed USD 1.5 billion by 2024. It is widely used owing to its preference to product complex therapeutic proteins and enhanced compatibility for posttranslational modifications. Monoclonal antibodies held more than 35% of the bioreactor market share in 2016, owing to increasing use in medical therapeutics attributed to its long half-life, high specificity, predictable pharmacokinetics, low toxicity, and high dose demand. The mAb therapeutics segment should flourish over the forecast years due to promising industry pipeline. Single use bubble column bioreactor market size should witness over 18% CAGR over the forecast years. It is extensively used for cell line development, process development, and clinical trial manufacturing wherein they enhance the overall speed and effectiveness of media and cell line development. U.S. bioreactor market size was valued at over USD 170 million in 2016 and is anticipated to witness significant growth over the coming years due to biopharmaceutical industry participants? focus on new drug development processes and growing number of strategic collaboration with academic institutions as well as venture capital firms. UK bioreactor market will witness over 17% CAGR, due to high healthcare spending and presence of large number of industry participants in this region. Increasing government initiatives to promote economic growth and improved quality of life should also drive industry growth. APAC will experience significant gains due to a trend shift from traditional methods to new production methods of monoclonal antibodies, recombinant proteins, and cell culturing by using advanced bioreactors. High demand for single-use bioreactors with continue to stimulate regional industry growth. Bioreactor market participants are Eppendorf, GE Healthcare, Merck Millipore, Sartorius, Thermo Fisher Scientific, etc. Industry participants engage in strategic collaborations, mergers & acquisitions coupled with new product launches in order to achieve competitive edge. Bioreactor market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2013 to 2024, for the following segments: Bioreactor Market, By Cell Mammalian cells Bacterial cells Yeast cells Other cells Bioreactor Market, By Molecule mAbs Vaccine Recombinant protein Stem cell Gene therapy Other molecules Bioreactor Market, By Technology Wave-induced motion SUB Stirred SUB Stirred use bubble column Other Bioreactor Market, By End Use Research and development (R&D) Biopharma manufacturers Contract manufacturing organisations (CMOs) The above information is provided for the following regions and countries: North America U.S. Canada Europe Germany UK France Spain Italy Netherlands Denmark Asia Pacific China India Japan South Korea Australia Singapore Latin America Brazil Mexico Middle East and Africa South Africa UAE

 

Report Content

Chapter 1. Methodology

1.1. Methodology

1.1.1. Initial data exploration

1.1.2. Statistical model and forecast

1.1.3. Industry insights and validation

1.1.4. Market definition and forecast parameters

1.2. Data sources

1.2.1. Primary

1.2.2. Secondary

Chapter 2. Executive Summary

2.1. Bioreactor industry 3600 synopsis, 2013 - 2024

2.1.1. Business trends

2.1.2. Product trends

2.1.3. Technology trends

2.1.4. End use trends

2.1.5. Regional trends

Chapter 3. Bioreactor Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2013 – 2024

3.3. Industry ecosystem analysis

3.3.1. Distribution channel analysis

3.3.2. Vendor matrix

3.4. Industry impact forces

3.4.1. Growth drivers

3.4.1.1. Growing biopharmaceuticals and biologics industry

3.4.1.2. Technological advancements in bioreactor

3.4.1.3. Growing orphan drugs developments

3.4.1.4. Increasing demand for personalized medicines

3.4.2. Industry pitfalls & challenges

3.4.2.1. Low capacity of single use bioreactor

3.4.2.2. Concerns regarding extractables

3.5. Regulatory landscape

3.5.1. U.S.

3.5.2. Canada

3.5.3. Germany

3.5.4. UK

3.5.5. China

3.6. Outsourcing landscape

3.7. Technology landscape

3.7.1. U.S.

3.7.2. Europe

3.8. Growth potential analysis

3.8.1. By Molecule

3.8.2. By Technology

3.9. Porter’s analysis

3.10. Bioreactor competitive landscape, 2016

3.10.1. Business overview

3.10.2. Revenue analysis

3.10.3. Product landscape

3.10.4. Strategy dashboard

3.11. PESTEL analysis

Chapter 4. Bioreactor Market, By Cell

4.1. Global bioreactor market share by cell, 2016 & 2024

4.2. Mammalian cells

4.2.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

4.3. Bacterial cells

4.3.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

4.4. Yeast cells

4.4.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

4.5. Other cells

4.5.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

Chapter 5. Bioreactor Market, By Molecule

5.1. Global bioreactor market share by molecule, 2016 & 2024

5.2. mAbs

5.2.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

5.3. Vaccine

5.3.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

5.4. Recombinant protein

5.4.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

5.5. Stem cell

5.5.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

5.6. Gene therapy

5.6.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

5.7. Other molecules

5.7.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

Chapter 6. Bioreactor Market, By Technology

6.1. Global bioreactor market share by technology, 2016 & 2024

6.2. Wave-induced motion SUB

6.2.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

6.3. Stirred SUB

6.3.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

6.4. Stirred use bubble column

6.4.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

6.5. Other

6.5.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

Chapter 7. Bioreactor Market, By End Use

7.1. Global bioreactor market share by end use, 2016 & 2024

7.2. Research and development (R&D)

7.2.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

7.3. Biopharma manufacturers

7.3.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

7.4. Contract manufacturing organisations (CMOs)

7.4.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

Chapter 8. Bioreactor Market, By Region

8.1. Bioreactor market share by region, 2016 & 2024

8.2. North America

8.2.1. Market estimates and forecast, by country, 2013 – 2024 (USD Million)

8.2.2. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.2.3. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.2.4. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.2.5. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.2.6. U.S.

8.2.6.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.2.6.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.2.6.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.2.6.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.2.7. Canada

8.2.7.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.2.7.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.2.7.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.2.7.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.3. Europe

8.3.1. Market estimates and forecast, by country, 2013 – 2024 (USD Million)

8.3.2. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.3.3. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.3.4. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.3.5. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.3.6. Germany

8.3.6.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.3.6.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.3.6.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.3.6.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.3.7. UK

8.3.7.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.3.7.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.3.7.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.3.7.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.3.8. Spain

8.3.8.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.3.8.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.3.8.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.3.8.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.3.9. Italy

8.3.9.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.3.9.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.3.9.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.3.9.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.3.10. France

8.3.10.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.3.10.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.3.10.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.3.10.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.3.11. Netherlands

8.3.11.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.3.11.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.3.11.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.3.11.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.3.12. Denmark

8.3.12.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.3.12.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.3.12.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.3.12.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.4. Asia Pacific

8.4.1. Market estimates and forecast, by country, 2013 – 2024 (USD Million)

8.4.2. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.4.3. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.4.4. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.4.5. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.4.6. China

8.4.6.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.4.6.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.4.6.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.4.6.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.4.7. Japan

8.4.7.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.4.7.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.4.7.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.4.7.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.4.8. India

8.4.8.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.4.8.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.4.8.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.4.8.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.4.9. South Korea

8.4.9.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.4.9.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.4.9.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.4.9.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.4.10. Australia

8.4.10.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.4.10.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.4.10.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.4.10.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.4.11. Singapore

8.4.11.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.4.11.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.4.11.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.4.11.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.5. Latin America

8.5.1. Market estimates and forecast, by country, 2013 – 2024 (USD Million)

8.5.2. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.5.3. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.5.4. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.5.5. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.5.6. Brazil

8.5.6.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.5.6.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.5.6.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.5.6.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.5.7. Mexico

8.5.7.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.5.7.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.5.7.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.5.7.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.6. Middle East & Africa

8.6.1. Market estimates and forecast, by country, 2013 – 2024 (USD Million)

8.6.2. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.6.3. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.6.4. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.6.5. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.6.6. South Africa

8.6.6.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.6.6.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.6.6.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.6.6.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

8.6.7. UAE

8.6.7.1. Market estimates and forecast, by cell, 2013 – 2024 (USD Million)

8.6.7.2. Market estimates and forecast, by molecule, 2013 – 2024 (USD Million)

8.6.7.3. Market estimates and forecast, by technology, 2013 – 2024 (USD Million)

8.6.7.4. Market estimates and forecast, by end use, 2013 – 2024 (USD Million)

Chapter 9. Company Profiles

9.1. Thermo Fisher Scientific

9.1.1. Business Overview

9.1.2. Financial Data

9.1.3. Product Landscape

9.1.4. Strategic Outlook

9.2. PBS Biotech

9.2.1. Business Overview

9.2.2. Financial Data

9.2.3. Product Landscape

9.2.4. Strategic Outlook

9.3. GE Healthcare

9.3.1. Business Overview

9.3.2. Financial Data

9.3.3. Product Landscape

9.3.4. Strategic Outlook

9.4. Merck Group

9.4.1. Business Overview

9.4.2. Financial Data

9.4.3. Product Landscape

9.4.4. Strategic Outlook

9.5. Cellexus Ltd

9.5.1. Business Overview

9.5.2. Financial Data

9.5.3. Product Landscape

9.5.4. Strategic Outlook

9.6. Pall Corporation

9.6.1. Business Overview

9.6.2. Financial Data

9.6.3. Product Landscape

9.6.4. Strategic Outlook

9.7. Sartorius Stedium Biotech Group

9.7.1. Business Overview

9.7.2. Financial Data

9.7.3. Product Landscape

9.7.4. Strategic Outlook

9.8. Applikon Biotechnology, Inc.

9.8.1. Business Overview

9.8.2. Financial Data

9.8.3. Product Landscape

9.8.4. Strategic Outlook

9.9. GEA Group Aktiengesellschaft

9.9.1. Business Overview

9.9.2. Financial Data

9.9.3. Product Landscape

9.9.4. Strategic Outlook

9.10. BioTron Inc.

9.10.1. Business Overview

9.10.2. Financial Data

9.10.3. Product Landscape

9.10.4. Strategic Outlook

9.11. Bbi Biotech

9.11.1. Business Overview

9.11.2. Financial Data

9.11.3. Product Landscape

9.11.4. Strategic Outlook

9.12. Bailun Bio

9.12.1. Business Overview

9.12.2. Financial Data

9.12.3. Product Landscape

9.12.4. Strategic Outlook

9.13. CerCell

9.13.1. Business Overview

9.13.2. Financial Data

9.13.3. Product Landscape

9.13.4. Strategic Outlook

9.14. Eppendorf

9.14.1. Business Overview

9.14.2. Financial Data

9.14.3. Product Landscape

9.14.4. Strategic Outlook

9.15. Solaris Biotech Solutions

9.15.1. Business Overview

9.15.2. Financial Data

9.15.3. Product Landscape

9.15.4. Strategic Outlook

9.16. Pierre Guerin Technologies

9.16.1. Business Overview

9.16.2. Financial Data

9.16.3. Product Landscape

9.16.4. Strategic Outlook

9.17. CESCO Bioengineering Co. Ltd.

9.17.1. Business Overview

9.17.2. Financial Data

9.17.3. Product Landscape

9.17.4. Strategic Outlook



Data Tables

TABLE 1 Bioreactor industry 3600 synopsis, 2013 – 2024

TABLE 2 Global bioreactor market, 2013-2024 (USD Million)

TABLE 3 Global bioreactor market, by cell, 2013-2024 (USD Million)

TABLE 4 Global bioreactor market, by molecule, 2013-2024 (USD Million)

TABLE 5 Global bioreactor market, by technology, 2013-2024 (USD Million)

TABLE 6 Global bioreactor market, by end use, 2013-2024 (USD Million)

TABLE 7 Global bioreactor market, by region, 2013-2024 (USD Million)

TABLE 8 Mammalian cells market, by region, 2013 – 2024 (USD Million)

TABLE 9 Bacterial cells market, by region, 2013 – 2024 (USD Million)

TABLE 10 Yeast cells market, by region, 2013 – 2024 (USD Million)

TABLE 11 Others market, by region, 2013 – 2024 (USD Million)

TABLE 12 Monoclonal antibodies market, by region, 2013 – 2024 (USD Million)

TABLE 13 Vaccine market, by region, 2013 – 2024 (USD Million)

TABLE 14 Recombinant protein market, by region, 2013 – 2024 (USD Million)

TABLE 15 Stem cell market, by region, 2013 – 2024 (USD Million)

TABLE 16 Gene therapy market, by region, 2013 – 2024 (USD Million)

TABLE 17 Other molecules market, by region, 2013 – 2024 (USD Million)

TABLE 18 Wave-induced motion SUB market by region, 2013 – 2024 (USD Million)

TABLE 19 Stirred SUB market, by region, 2013 - 2024, (USD Million)

TABLE 20 Single use bubble column market, by region, 2013 - 2024, (USD Million)

TABLE 21 Others market, by region, 2013 – 2024, (USD Million)

TABLE 22 R&D market, by region, 2013–2024 (USD Million)

TABLE 23 Biopharma manufacturers market, by region, 2013–2024 (USD Million)

TABLE 24 Contract manufacturing organisations market, by region, 2013–2024 (USD Million)

TABLE 25 North America bioreactor market, by country, 2013 – 2024 (USD Million)

TABLE 26 North America bioreactor market, by cell, 2013 – 2024 (USD Million)

TABLE 27 North America bioreactor market, by molecule, 2013 – 2024 (USD Million)

TABLE 28 North America bioreactor market, by technology, 2013 – 2024 (USD Million)

TABLE 29 North America bioreactor market, by end use, 2013 – 2024 (USD Million)

TABLE 30 U.S. bioreactor market, by cell, 2013 – 2024 (USD Million)

TABLE 31 U.S. bioreactor market, by molecule, 2013 – 2024 (USD Million)

TABLE 32 U.S. bioreactor market, by technology, 2013 – 2024 (USD Million)

TABLE 33 U.S. bioreactor market, by end use, 2013 – 2024 (USD Million)

TABLE 34 Canada bioreactor market, by cell, 2013 – 2024 (USD Million)

TABLE 35 Canada bioreactor market, by molecule, 2013 – 2024 (USD Million)

TABLE 36 Canada bioreactor market, by technology, 2013 – 2024 (USD Million)

TABLE 37 Canada bioreactor market, by end use, 2013 – 2024 (USD Million)

TABLE 38 Europe bioreactor market, by country, 2013 – 2024 (USD Million)

TABLE 39 Europe bioreactor market, by cell, 2013 – 2024 (USD Million)

TABLE 40 Europe bioreactor market, by molecule, 2013 – 2024 (Million)

TABLE 41 Europe bioreactor market, by technology, 2013 – 2024 (Million)

TABLE 42 Europe bioreactor market, by end use, 2013 – 2024 (Million)

TABLE 43 Germany bioreactor market, by cell, 2013 – 2024 (USD Million)

TABLE 44 Germany bioreactor market, by molecule, 2013 – 2024 (Million)

TABLE 45 Germany bioreactor market, by technology, 2013 – 2024 (Million)

TABLE 46 Germany bioreactor market, by end use, 2013 – 2024 (Million)

TABLE 47 UK bioreactor market, by cell, 2013 – 2024 (USD Million)

TABLE 48 UK bioreactor market, by molecule, 2013 – 2024 (Million)

TABLE 49 UK bioreactor market, by technology, 2013 – 2024 (Million)

TABLE 50 UK bioreactor market, by end use, 2013 – 2024 (Million)

TABLE 51 Spain bioreactor market, by cell, 2013 – 2024 (USD Million)

TABLE 52 Spain bioreactor market, by molecule, 2013 – 2024 (Million)

TABLE 53 Spain bioreactor market, by technology, 2013 – 2024 (Million)

TABLE 54 Spain bioreactor market, by end use, 2013 – 2024 (Million)

TABLE 55 Italy bioreactor market, by cell, 2013 – 2024 (USD Million)

TABLE 56 Italy bioreactor market, by molecule, 2013 – 2024 (Million)

TABLE 57 Italy bioreactor market, by technology, 2013 – 2024 (Million)

TABLE 58 Italy bioreactor market, by end use, 2013 – 2024 (Million)

TABLE 59 France bioreactor market, by cell, 2013 – 2024 (USD Million)

TABLE 60 France bioreactor market, by molecule, 2013 – 2024 (Million)

TABLE 61 France bioreactor market, by technology, 2013 – 2024 (Million)

TABLE 62 France bioreactor market, by end use, 2013 – 2024 (Million)

TABLE 63 Netherlands bioreactor market, by cell, 2013 – 2024 (USD Million)

TABLE 64 Netherlands bioreactor market, by molecule, 2013 – 2024 (Million)

TABLE 65 Netherlands bioreactor market, by technology, 2013 – 2024 (Million)

TABLE 66 Netherlands bioreactor market, by end use, 2013 – 2024 (Million)

TABLE 67 Denmark bioreactor market, by cell, 2013 – 2024 (USD Million)

TABLE 68 Denmark bioreactor market, by molecule, 2013 – 2024 (Million)

TABLE 69 Denmark bioreactor market, by technology, 2013 – 2024 (Million)

TABLE 70 Denmark bioreactor market, by end use, 2013 – 2024 (Million)

TABLE 71 Asia Pacific bioreactor market, by country, 2013–2024 (USD Million)

TABLE 72 Asia Pacific bioreactor market, by cell, 2013–2024 (USD Million)

TABLE 73 Asia Pacific bioreactor market, by molecule, 2013–2024 (USD Million)

TABLE 74 Asia Pacific bioreactor market, by technology, 2013–2024 (USD million)

TABLE 75 Asia Pacific bioreactor market, by end use, 2013–2024 (USD Million)

TABLE 76 China bioreactor market, by cell, 2013–2024 (USD Million)

TABLE 77 China bioreactor market, by molecule, 2013–2024 (USD Million)

TABLE 78 China bioreactor market, by technology, 2013–2024 (USD million)

TABLE 79 China bioreactor market, by end use, 2013–2024 (USD Million)

TABLE 80 Japan bioreactor market, by cell, 2013–2024 (USD Million)

TABLE 81 Japan bioreactor market, by molecule, 2013–2024 (USD Million)

TABLE 82 Japan bioreactor market, by technology, 2013–2024 (USD million)

TABLE 83 Japan bioreactor market, by end use, 2013–2024 (USD Million)

TABLE 84 India bioreactor market, by cell, 2013–2024 (USD Million)

TABLE 85 India bioreactor market, by molecule, 2013–2024 (USD Million)

TABLE 86 India bioreactor market, by technology, 2013–2024 (USD million)

TABLE 87 India bioreactor market, by end use, 2013–2024 (USD Million)

TABLE 88 South Korea bioreactor market, by cell, 2013–2024 (USD Million)

TABLE 89 South Korea bioreactor market, by molecule, 2013–2024 (USD Million)

TABLE 90 South Korea bioreactor market, by technology, 2013–2024 (USD million)

TABLE 91 South Korea bioreactor market, by end use, 2013–2024 (USD Million)

TABLE 92 Australia bioreactor market, by cell, 2013–2024 (USD Million)

TABLE 93 Australia bioreactor market, by molecule, 2013–2024 (USD Million)

TABLE 94 Australia bioreactor market, by technology, 2013–2024 (USD million)

TABLE 95 Australia bioreactor market, by end use, 2013–2024 (USD Million)

TABLE 96 Singapore bioreactor market, by cell, 2013–2024 (USD Million)

TABLE 97 Singapore bioreactor market, by molecule, 2013–2024 (USD Million)

TABLE 98 Singapore bioreactor market, by technology, 2013–2024 (USD million)

TABLE 99 Singapore bioreactor market, by end use, 2013–2024 (USD Million)

TABLE 100 Latin America bioreactor market, by country, 2013- 2024, (USD Million)

TABLE 101 Latin America bioreactor market, by cell, 2013- 2024, (USD Million)

TABLE 102 Latin America bioreactor market, by molecule, 2013 - 2024, (USD Million)

TABLE 103 Latin America bioreactor market, by technology, 2013 - 2024, (USD Million)

TABLE 104 Latin America bioreactor market, by end-use, 2013 - 2024, (USD Million)

TABLE 105 Brazil bioreactor market, by cell, 2013- 2024, (USD Million)

TABLE 106 Brazil bioreactor market, by molecule, 2013 - 2024, (USD Million)

TABLE 107 Brazil bioreactor market, by technology, 2013 - 2024, (USD Million)

TABLE 108 Brazil bioreactor market, by end-use, 2013 - 2024, (USD Million)

TABLE 109 Mexico bioreactor market, by cell, 2013- 2024, (USD Million)

TABLE 110 Mexico bioreactor market, by molecule, 2013 - 2024, (USD Million)

TABLE 111 Mexico bioreactor market, by technology, 2013 - 2024, (USD Million)

TABLE 112 Mexico bioreactor market, by end-use, 2013 - 2024, (USD Million)

TABLE 113 MEA bioreactor market, by country, 2013- 2024, (USD Million)

TABLE 114 MEA bioreactor market, by cell, 2013- 2024, (USD Million)

TABLE 115 MEA bioreactor market, by molecule, 2013 - 2024, (USD Million)

TABLE 116 MEA bioreactor market, by technology, 2013 - 2024, (USD Million)

TABLE 117 MEA bioreactor market, by end-use, 2013 - 2024, (USD Million)

TABLE 118 UAE bioreactor market, by cell, 2013- 2024, (USD Million)

TABLE 119 UAE bioreactor market, by molecule, 2013 - 2024, (USD Million)

TABLE 120 UAE bioreactor market, by technology, 2013 - 2024, (USD Million)

TABLE 121 UAE bioreactor market, by end-use, 2013 - 2024, (USD Million)

TABLE 122 South Africa bioreactor market, by cell, 2013- 2024, (USD Million)

TABLE 123 South Africa bioreactor market, by molecule, 2013 - 2024, (USD Million)

TABLE 124 South Africa bioreactor market, by technology, 2013 - 2024, (USD Million)

TABLE 125 South Africa bioreactor market, by end-use, 2013 - 2024, (USD Million)

Charts & Figures

FIG. 1 Industry segmentation

FIG. 2 Global bioreactor market, 2013 - 2024 (USD Million)

FIG. 3 Industry ecosystem analysis

FIG. 4 Distribution channel analysis

FIG. 5 Vendor matrix

FIG. 6 Growth potential analysis

FIG. 7 Porter’s analysis

FIG. 8 Competitive landscape, 2014 - 2017

FIG. 9 Strategic dashboard

FIG. 10 PESTEL analysis

FIG. 11 Bioreactor market share by cell, 2016 & 2024

FIG. 12 Bioreactor market share by molecule, 2016 & 2024

FIG. 13 Bioreactor market share by technology, 2016 & 2024

FIG. 14 Bioreactor market share by end-use, 2016 & 2024

FIG. 15 Bioreactor market share, by region, 2016 & 2024


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Market Insights, Inc.

Minoxidil Market Size By Product (5%, 2%), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Russia, Poland, China, India, Japan, South Korea, Indonesia, Thailand, Malaysia, Australia, Brazil, Mexico, Argentina, Saudi Arabia, UAE, South Africa), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2018 - 2024

Minoxidil market is projected to exceed USD 1 billion by 2024. Rising disposable income in conjunction with urbanization is propelling the hair care product demand, thereby positively influencing industry growth. Unhealthy lifestyles accompanied by e...

New Biotechnology Reports